|
Main
|
|
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
17 October 2012 |
|
Main ID: |
NCT00517348 |
|
Date of registration:
|
14/08/2007 |
|
Primary sponsor: |
|
|
Public title:
|
Study Evaluating IMA-026 in Healthy Subjects
|
|
Scientific title:
|
Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IMA-026 Administered Subcutaneously or Intravenously to Healthy Subjects |
|
Date of first enrolment:
|
September 2007 |
|
Target sample size:
|
50 |
|
Recruitment status: |
Completed |
|
URL:
|
http://clinicaltrials.gov/show/NCT00517348 |
|
Study type:
|
Interventional |
|
Study design:
|
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
|
|
|
Countries of recruitment
|
|
United States
| | | | | | | |
|
Contacts
|
|
Name:
|
Medical Monitor |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Wyeth is now a wholly owned subsidiary of Pfizer |
| | |
|
Key inclusion & exclusion criteria
|
- Healthy men and women ages 18 - 50
- Body weight greater than or equal to 50 kilograms
- Nonsmoker or fewer than 10 cigarettes per day
- No serious infection, i.e., requiring hospitalization or IV antibiotics, or an upper
respiratory infection within 1 month before dosing
Age minimum:
18 Years
Age maximum:
50 Years
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Healthy
|
|
Intervention(s)
|
|
Biological: IMA-026
|
|
Primary Outcome(s)
|
|
Pharmacokinetic (PK) analysis
[Time Frame: 6 months]
|
|
Secondary ID(s)
|
|
3192K1-1000
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|